Table 3.
Anti ALK ab + patient's characteristics (n = 5).
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
|---|---|---|---|---|---|
| Plasma | 70079 | 84396 | 117083 | 1105 | 1238 |
| Titer | +1:100 | +1:250 | +1:2250 | +1:50 | +1:750 |
| Histology | adeno | adeno | Adeno | adeno | adeno |
| ALK+ | IHC | IHC/FISH | IHC | IHC/FISH | IHC |
| Sex | male | male | female | male | Female |
| Smoking history | Former 25 P/Y |
Former 1 P/Y |
no | Former 40 P/Y |
Former 15 P/Y |
| Age at diagnosis | 58 | 23 | 36 | 69 | 43 |
| Stage at diagnosis | IV | IV | IV | IIIB | IIIC |
| BM baseline/PD | 0/0 | 0/0 | 0/0 | 0/0 | 0/1 |
| PC after diagnosis (m) | 30.7 | 19.5 | 31.3 | 13.5 | 6.0 |
| 1st line ALK- TKI | crizotinib | crizotinib | crizotinib | crizotinib | crizotinib |
| PFS1 (m) | 3.4 | 14.5 | 8.7 | 9.3 | 4.5 |
| Brain PD | 0 | 0 | 0 | 0 | 1 |
| OS status | Alive | Death | Death | Death | Death |
| OS (m) | 87.3 | 19.9 | 55.4 | 14.2 | 40.3 |
| Co-molecular alterations | NA | ALK F1174N, PIK3CB |
ALK G1202R, ROS1 T1987K |
ALK G1269A, ALK F1174L, PIK3CB | TP53 |
BM = brain metastases; PC = plasma collection; (m) = months; PFS1 = progression free survival on 1st ALK-TKI; OS = overall survival.